Combination immuno-oncology therapy with immune checkpoint blockers targeting PD-L1, PD-1 or CTLA4 and epigenetic drugs targeting MYC and immune evasion for precision medicine

Ítems similars

• Combination immuno-oncology therapy with pembrolizumab, an anti-PD-1 monoclonal antibody targeting immune evasion, and standard chemotherapy for patients with the squamous and non-squamous subtypes of non-small cell lung cancer
  per: Katoh, Masaru
  Publicat: (2018)
• Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
  per: Qin, Shuang, et al.
  Publicat: (2019)
• Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
  per: Hyun Tae Lee, et al.
  Publicat: (2019-03-01)
• Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
  per: Lee, Hyun Tae, et al.
  Publicat: (2019)
• The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1
  per: Derosa, Lisa, et al.
  Publicat: (2018)